AAL is down -4.68% to about $12.01 during regular trading, erasing the prior session's post-earnings rebound. Primary catalyst: jet fuel/oil hit a five-month high on renewed U.S.-Iran conflict concerns, squeezing airline margins.

BEX, a 2x leveraged single-stock ETF tracking Bloom Energy (BE), is down -19.30% in today's regular session (last ~$17.14 vs. prior close $21.24). The drop mirrors a sharp intraday pullback in underlying BE shares, with BEX's daily 2x structure roughly doubling the underlying move.

FIX is trading down -8.49% to roughly $1,170.72 during regular market hours, extending a post-earnings slide from Thursday's $1,279.37 close. The move follows Q3 results that beat estimates (EPS $13.91 vs. $12.85; revenue $3.77B vs. ~$3.40B) but offered no forward guidance and disclosed CFO Bill George's planned retirement.

BE is down -10.09% to $195.79 during the regular session, extending an after-hours slide from Thursday's close of $217.77. The drop follows Q3 results that beat estimates (adjusted EPS $0.94 vs $0.69; revenue +138% to $1.24B), but record capex of $153M and -$180.6M free cash flow spooked investors.

SHFS is down roughly -37% intraday, trading near $0.22 after closing at $0.3429 (+122%) in the prior session. The decline is occurring during regular market hours as the previous-session spike unwinds.

LABT is trading down -34.69% to roughly $0.32 during the regular session, versus a $0.49 close on Oct 22. The drop reversed an overnight premarket spike of +56.8% to $0.77, sparked by a preclinical Nu-3 data presentation announcement.

BURU closed down -5.83% to $0.4101 during regular trading on Oct 22, versus a $0.4355 prior close. The decline came despite positive news, including the Tekne CEO appointment and a $17.1M special-vehicle program update.

AARD is down about -49.87% intraday (near $1.98) during regular trading, erasing an after-hours pop that followed the FDA's lifting of the ARD-101 clinical hold. The primary catalyst: this morning's exploratory data from the terminated Phase 3 HERO/OLE trials showed only modest hyperphagia (HQ-CT) improvements, with just 67 of 90 patients enrolled and results not powered for efficacy.

VZLA is trading down -7.84% to about $2.94 during regular market hours, extending a decline from its prior close of $3.19. The primary catalyst is a sharp drop in silver, with spot prices sliding over -2% to roughly $53.47/oz, pressuring silver producers.

OLMA shares fell -6.98% to about $6.53 during regular market hours, down from a prior close of $7.02. The decline came without a company-specific catalyst, reflecting continued sector-wide de-risking in oral SERD/breast-cancer biotechs.

HRI is trading down -5.05% to $126.80 during regular market hours, versus a prior close of $133.55. The slide follows JPMorgan lowering its price target to $165 from $175 while keeping an Overweight rating, adding to cautious sentiment ahead of results.

BLMN is trading down roughly -5.55% during the regular session, near $9.70 versus a prior close of $10.27. The decline is sector-driven rather than company-specific, with no BLMN earnings today (Q3 results are scheduled for November 6).

American Airlines (AAL) is down -5.71% today, trading near $11.88 versus the prior close of $12.60, during regular market hours. The drop reverses Thursday's post-earnings rebound as oil hit a five-month high on renewed U.S.-Iran tensions, worsening the carrier's fuel-cost exposure.

SION is down -5.26% in regular trading, slipping to about $3.60 from a prior close of $3.80. The decline extends a weeks-long selloff following the failed SION-719 Phase 2a cystic fibrosis trial and the resulting 46% workforce reduction and restructuring.

PBLS is trading down -6.91% (roughly -$1.86 to about $25.06 from a $26.92 prior close) during regular market hours. The decline extends a post-IPO unwind and profit-taking, with shares down roughly -39% over the past month despite recent positive headlines.

ARCT dropped -6.43% during regular trading, sliding to $10.04 from Wednesday's $10.73 close. The decline extends a month-long pullback of roughly -25% as momentum fades following a sharp ~+94% three-month rally.

QDEL is trading down -6.01% to $12.67 during regular market hours, extending a -4.26% decline from the prior session close of $13.48. The move reflects ongoing pressure from China's proposed IVD pricing guidelines and softer respiratory testing demand, which drove a lowered 2026 outlook after the Q2 report.

IRLA closed down -5.33% to $32.83 during regular trading on Oct 22, extending a -13.88% slide from the prior session. No single company headline drove the move; it reflects post-relaunch volatility following the Oct 9 reverse-merger rebrand from Quince Therapeutics (QNCX) to IRulya Therapeutics, amplified by thin liquidity.

CWH is down -6.84% during regular trading hours, sliding to roughly $4.22 from a $4.53 prior-session close. The decline extends ongoing selling pressure after the company's October filing signaled it will miss its 2026 adjusted EBITDA guidance amid a soft RV market and elevated financing costs.

IMRX is trading down -4.72% to about $3.63 from a prior close of $3.81, with the decline occurring during regular market hours. No company-specific release was identified today; the move reflects broad biotech-sector weakness and profit-taking after a recent premarket bounce near its 52-week low.